Anti-Diabetes Drugs - Central Africa

Central Africa

The Anti-Diabetes Drugs market in Central Africa is expected to witness a significant increase in revenue, reaching a projected amount of US$74.47m in 2024.
This market is also anticipated to demonstrate a steady annual growth rate of 7.07% from 2024 to 2029, leading to a market volume of US$104.80m by the end of 2029.
When compared globally, United States is forecasted to generate the highest revenue in this market, with a staggering amount of US$37,840.00m in 2024.
Central Africa's anti-diabetes drug market is experiencing a surge in demand due to the rising prevalence of diabetes in the region.

Key regions: India, Australia, Italy, Europe, Brazil

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Diabetes Drugs market in Central Africa has been showing an upward trend in recent years.

Customer preferences: Central Africa has a high prevalence of diabetes, which has resulted in a significant increase in the demand for anti-diabetes drugs. Patients in the region prefer medications that are affordable and effective in managing their condition.

Trends in the market: The market for anti-diabetes drugs in Central Africa has been growing due to the increasing number of people diagnosed with diabetes. The region has also witnessed a rise in the number of generic drugs available in the market, which has made treatment more accessible and affordable for patients.

Local special circumstances: Central Africa faces several challenges in managing diabetes, including a lack of healthcare infrastructure, limited access to medications, and poor awareness of the disease. These challenges have led to a significant burden on the healthcare system and have resulted in a high rate of complications and mortality.

Underlying macroeconomic factors: The economic growth in Central Africa has been slow, which has resulted in a lack of investment in the healthcare sector. The region also faces political instability and security challenges, which have made it difficult to implement effective healthcare policies. These factors have contributed to the challenges in managing diabetes in the region.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.